Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
April 1, 2022
PASADENA, Calif.--(BUSINESS WIRE)--Apr. 1, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to
participate in the following upcoming events:
- 31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) – March 30-April 3, 2022
-- Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically
Impaired Participants
Authors: Thomas N. Kakuda, et al.
-- Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants
Authors: Haiyan Li, et al.
-- Title: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no
correlate was identified for HBsAg reduction and baseline factors
Authors: Edward Gane, et al.
- American Association for Cancer Research Annual Meeting 2022 (AACR) – April 8-13, 2022
Title: Targeting HIF2a with siRNA: From preclinical models to the clinic
Authors: Yuanqing Ma, et al.
- DIA/FDA's Oligonucleotide-based Therapeutics Conference (Oligo22) – April 25-27, 2022
-- Title: Short Interfering RNA JNJ-3989 Combination Therapy
Presenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals
-- Title: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial
Presenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals